宁波泰斯拓生物

www.testobio.com
  • 本公司产品仅供体外研究使用,不用于临床诊断
首页  /  产品中心  /  进口菌株

产品中心

试剂盒
菌株
质粒
试剂
联系我们  CONTACT US

0574-87917803

testobio@163.com

浙江省宁波市镇海区庄市街道兴庄路9号创e慧谷42号楼B幢401室
最新促销

货号: TS263591

名称: Candida metapsilosis


货号: TS263592

名称: Candida sake


货号: TS131909

名称: HFBCI28


货号: TS131910

名称: Septoria passiflorae Sydow, anamorph


货号: TS131911

名称: Graphium cuneiferum (Berkeley et Broome) Mason et Ellis


货号: TS131912

名称: Streptomyces scabiei (Thaxter) Lambert and Loria


货号: TSTOA0001

名称: Marisediminicola antarctica


货号: TS276951

名称: Real Time PCR EasyTM-Taqman


货号: TS276952

名称: Bacillus subtilis


货号: TS276954

名称: Bacillus subtilis

CT26.CL25

货号 TS212326
中文名称 null
适应种属
检测范围
微信小陈 微信小章
在线留言
产品简介
购买须知
产品名称: CT26.CL25
商品货号: TS212326
Organism: Mus musculus, mouse
Tissue: colon
Product Format: frozen
Morphology: fibroblast
Culture Properties: adherent
Biosafety Level: 2 xa0Cells contain SV40 viral DNA sequences

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease: carcinoma, derived from colon
Strain: BALB/c
Applications:
The cell line can be used as a model for testing immunotherapy protocols and in studies on the host immune response.
Storage Conditions: liquid nitrogen vapor temperature
Derivation:
CT26 is an N-nitroso-N-methylurethane-(NNMU) induced, undifferentiated colon carcinoma cell line. It was cloned to generate the cell line designated CT26.WT (ATCC CRL-2638).
CT26.WT was stably transduced with the retroviral vector LXSN that contains the lacZ gene encoding the model tumor associated antigen (TAA), beta-galactosidase (beta-gal).
The cells were grown in G418 for seven days, cloned, and evaluated for beta-gal production.
The lethal subclone CT26.CL25 (TS212326) was selected for use in all in vitro and in vivo studies because of its stable high expression of both beta-gal and the class I molecule H-2 Ld.
Clinical Data:
The cell line can be used as a model for testing immunotherapy protocols and in studies on the host immune response.
Antigen Expression:
H-2d
Genes Expressed:
beta galactosidase (beta-gal),H-2d,The lethal subclone CT26.CL25 (TS212326) was selected for use in all in vitro and in vivo studies because of its stable high expression of both beta-gal and the class I molecule H-2 Ld.
The cell line can be used with CT26.CL25 (TS212326) as a model for testing immunotherapy protocols and in studies on the host immune response.
Cellular Products:
beta galactosidase (beta-gal)
Tumorigenic: Yes
Effects:
Yes, in BALB/c mice. Mice inoculated, subcutaneously, developed lethal tumors at 80% frequency with 10 exp3 cells and at 100% with 10 exp4 cells. Pulmonary metastases developed when mice were inoculated, intravenously, with 10 exp4 cells.
Comments:
CT26 is an N-nitroso-N-methylurethane-(NNMU) induced, undifferentiated colon carcinoma cell line. It was cloned to generate the cell line designated CT26.WT (ATCC CRL-2638).
CT26.WT was stably transduced with the retroviral vector LXSN that contains the lacZ gene encoding the model tumor associated antigen (TAA), beta-galactosidase (beta-gal).
The vector is driven by the Moloney murine leukemia virus (MoMuLV) long terminal repeat (LTR) promoter and contains a gene controlling resistance to neomycin transcribed from the SV40 promoter.
The cells were grown in G418 for seven days, cloned, and evaluated for beta-gal production.
The lethal subclone CT26.CL25 (TS212326) was selected for use in all in vitro and in vivo studies because of its stable high expression of both beta-gal and the class I molecule H-2 Ld.
The growth rate and lethality of CT26.CL25 and CT26.WT is virtually identical despite the expression by CT26.CL25 of the model TAA, beta-galactosidase, in normal mice.
The cell line can be used as a model for testing immunotherapy protocols and in studies on the host immune response.
Complete Growth Medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES and 1.0 mM sodium pyruvate and supplemented with 0.1 mM non-essential amino-acids and 0.4 mg/ml G418, 90%; fetal bovine serum, 10%
Subculturing: Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Note: Subculture at 80% confluence. Cells pile up and do not become completely confluent.

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin-0.03% (w/v) EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C

Subculture ratio: 1:4 to 1:6
Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994

Cryopreservation:
Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor temperature
Culture Conditions:
Temperature: 37.0°C
Name of Depositor: N Restifo
Deposited As: mouse
References:

Wang M, et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J. Immunol. 154: 4685-4692, 1995. PubMed: 7722321

Chen PW, et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156: 224-231, 1996. PubMed: 8598466

Irvine KR, et al. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 156: 238-245, 1996. PubMed: 8598468

Carroll MW, et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15: 387-394, 1997. PubMed: 9141209